AbbVie, Amgen and Sanofi could swoop in for AZ, but numbers may not work

Save

AstraZeneca is none too thrilled with Pfizer's £58.8 billion ($98.7 billion) takeover proposal, it said Monday. Analysts do see some potential white knights that could offer up their own bids for the British drugmaker. But the problem for AstraZeneca is this: They don't match up as well as Pfizer does, they say.